EP1100477B1 - Pflaster, die zur transdermalen Applikation von Estradiol geeignet sind, und Wollwachs oder Bestandteile davon sowie Zinkoxid enthalten - Google Patents

Pflaster, die zur transdermalen Applikation von Estradiol geeignet sind, und Wollwachs oder Bestandteile davon sowie Zinkoxid enthalten Download PDF

Info

Publication number
EP1100477B1
EP1100477B1 EP99936555A EP99936555A EP1100477B1 EP 1100477 B1 EP1100477 B1 EP 1100477B1 EP 99936555 A EP99936555 A EP 99936555A EP 99936555 A EP99936555 A EP 99936555A EP 1100477 B1 EP1100477 B1 EP 1100477B1
Authority
EP
European Patent Office
Prior art keywords
active substance
containing patch
patch according
pressure
reservoir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP99936555A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1100477A1 (de
Inventor
Elvira Kirstgen
Reinhold Meconi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTS Lohmann Therapie Systeme AG
Original Assignee
LTS Lohmann Therapie Systeme AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7875613&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1100477(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by LTS Lohmann Therapie Systeme AG filed Critical LTS Lohmann Therapie Systeme AG
Publication of EP1100477A1 publication Critical patent/EP1100477A1/de
Application granted granted Critical
Publication of EP1100477B1 publication Critical patent/EP1100477B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0208—Tissues; Wipes; Patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0241—Containing particulates characterized by their shape and/or structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/60—Particulates further characterized by their structure or composition
    • A61K2800/65—Characterized by the composition of the particulate/core
    • A61K2800/651—The particulate/core comprising inorganic material

Definitions

  • the invention relates to a medicated plaster for controlled delivery of estradiol or its pharmaceutical harmless derivatives alone or in combination with gestagens to human or animal skin.
  • Estrogen and / or gestagen-containing plasters are already known. However, they have the disadvantages that they either Contain ethanol or pose a potential hazard, that the drug recrystallizes over time.
  • EP 0 285 563 describes a transdermal therapeutic System for the combined administration of estrogens and progestins.
  • the reservoir receives the drug formulation and optionally a membrane and ethanol as percutaneous absorption enhancing agent. Because the release the active ingredient is mainly controlled by the membrane is different, this transdermal therapeutic System in principle of the active ingredient patch according to the present invention.
  • the glue has been described there Plaster only the function, the plaster to attach to the skin. That he contributes to the steering to release the drug is not his main task, but only one - possibly even unwanted - side effect. These are to a so-called "bag plaster", since the drug preparation in a bag consisting of impermeable Backing layer and membrane with adhesive layer is located. As a result its complex structure is the production of the plaster very expensive, since the individual components are manufactured separately and then in a further operation to a Plaster must be put together.
  • EP 0 275 716 describes a - in contrast to the erfindugswashen single-layer system - two-layered transdermal system for the simultaneous administration of one or more estrogens dissolved in the polymer layer or are microdispersed.
  • the adhesive layer contains except the active substances, which are the transdermal absorption improve.
  • Polymer and adhesive layers can off Polyaxrylaten, silicones or polyisobutylenes exist.
  • EP 0 328 806 describes a membrane-free transdermal therapeutic system whose matrix consists of a polyacrylate adhesive, a solvent, a penetration improver and estrogens, their derivatives and combinations thereof consists.
  • WO 87/07138 is an estradiol patch with a Backing layer, a matrix containing the active substance and a pressure-sensitive adhesive that comes with a removable protective layer is covered described.
  • the production of matrix and pressure sensitive adhesives are technologically very complex Operations by homogenizing, degassing, coating, Drying and separating.
  • the backing layer must even be coated with a pressure-sensitive adhesive would, which requires a further operation.
  • the assembly of the individual parts takes place in a separate Operation.
  • the production of the plaster is so overall very complicated and complicated.
  • EP 0 186 019 discloses active substance patches known in which a rubber / adhesive resin mass in water swellable polymers are added and from which estradiol can be released. However, it has been shown that the release of estradiol from these drug patches far too low and not the therapeutic requirements equivalent.
  • DE-OS 20 06 969 is a plaster or an adhesive dressing described with systemic effect, in which contraceptive Substances in the adhesive component or the Adhesive film are incorporated.
  • the adhesive film can be Be acrylate.
  • Wool wax is known as a pharmaceutical raw material and as those described in the pharmacopoeias. It is used because of its ability to liberate active ingredients, its Skin friendliness and its water absorption capacity.
  • Zinc oxide is also described in the pharmacopoeias. zinc oxide acts as a mild disinfectant and anti-inflammatory, about it In addition, it reacts weakly alkaline.
  • the active ingredient-containing patch according to the invention can be used for cosmetic and for the manufacture of a preparation for therapeutic purposes in the human and Veterinary medicine can be used.
  • the recrystallization free estrogen and / or gestagen restroom Plaster with sufficient drug release contains in the reservoir estradiol and its pharmaceutically harmless Derivatives alone or in combination with progestins in a total concentration of 1-20% by weight on the totality of the reservoir components, and although in a molar ratio of 1: 1 to 1:10.
  • the estradiol Washington reservoir can at least one component the group containing which anti-aging agents, Plasticizers, antioxidants and absorption improvers includes. Suitable plasticizers are known to the person skilled in the art and For example, described in DE 37 43 946.
  • the estradiol Crow Reservoir typically contains plasticizer in a share of up to 5% by weight.
  • anti-aging agents in a concentration of up to 1% by weight contain. These are known in the art and e.g. in the DE 37 43 946 described.
  • the materials for the impermeable backing layer and the redetachable protective layer are also known to the person skilled in the art.
  • the estradiol Waste reservoir can from solution, from dispersion and also be produced from the melt.
  • the reservoir can consist of several layers.
  • a particularly preferred structure of the transdermal estradiol-containing Pflasters is a matrix system in which known the matrix controls the drug release takes over and obeys the ⁇ t-law according to Higuchi. This does not mean that not in special cases a membrane system is also an advantage. Here is between Reservoir and pressure-sensitive adhesive layer a the drug release controlling membrane attached.
  • the thickness of the transdermal patch depends on the therapeutic requirements and can be adapted accordingly become. It is usually in the range of 0.03-0.6 mm.
  • the skin is clamped in the Franz cell.
  • An estrogen- and / or gestagen-containing patch having an area of 1.539 cm 2 is adhered to the skin and the release of active ingredient is measured at 37 ° C. (acceptor medium: 0.9% saline + 0.1% NaN 3 ).
  • the recrystallization test becomes visual performed in backlight.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
EP99936555A 1998-07-29 1999-07-16 Pflaster, die zur transdermalen Applikation von Estradiol geeignet sind, und Wollwachs oder Bestandteile davon sowie Zinkoxid enthalten Expired - Lifetime EP1100477B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19834007 1998-07-29
DE19834007A DE19834007C1 (de) 1998-07-29 1998-07-29 Estradiolhaltiges Pflaster zur transdermalen Applikation von Hormonen und seine Verwendung
PCT/EP1999/005085 WO2000006131A1 (de) 1998-07-29 1999-07-16 Estradiolhaltiges pflaster zur transdermalen applikation von hormonen

Publications (2)

Publication Number Publication Date
EP1100477A1 EP1100477A1 (de) 2001-05-23
EP1100477B1 true EP1100477B1 (de) 2004-04-14

Family

ID=7875613

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99936555A Expired - Lifetime EP1100477B1 (de) 1998-07-29 1999-07-16 Pflaster, die zur transdermalen Applikation von Estradiol geeignet sind, und Wollwachs oder Bestandteile davon sowie Zinkoxid enthalten

Country Status (18)

Country Link
US (1) US6531149B1 (pl)
EP (1) EP1100477B1 (pl)
JP (1) JP2002521427A (pl)
KR (1) KR100559089B1 (pl)
CN (1) CN1172661C (pl)
AR (1) AR021459A1 (pl)
AT (1) ATE264097T1 (pl)
AU (1) AU758107B2 (pl)
BR (1) BR9912687A (pl)
CA (1) CA2338859C (pl)
DE (2) DE19834007C1 (pl)
ES (1) ES2220093T3 (pl)
IL (2) IL141033A0 (pl)
PL (1) PL194102B1 (pl)
TR (1) TR200100289T2 (pl)
TW (1) TW542726B (pl)
WO (1) WO2000006131A1 (pl)
ZA (1) ZA200100719B (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10304988A1 (de) * 2003-02-07 2004-09-09 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System mit verbessertem Hautklebeverhalten
EP1620459A4 (en) * 2003-05-07 2007-06-06 Cedars Sinai Medical Center INTRACELLULAR ESTRADIOL BINDING PROTEIN, POLYNUCLEOTIDE ENCODING THE SAME, AND CELL LINES EXPRESSING THE SAME
US7251128B2 (en) * 2004-09-30 2007-07-31 Intel Corporation Adjustable portable computer
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
HUE055562T2 (hu) 2011-11-23 2021-11-29 Therapeuticsmd Inc Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE251567C (pl)
NL6902314A (pl) 1969-02-13 1970-08-17
US3637224A (en) 1969-02-27 1972-01-25 Fedders Corp Annular sealing ring
US4379454A (en) 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
CA1248450A (en) * 1984-04-05 1989-01-10 Kazuo Kigasawa Soft patch
US4624665A (en) 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US4720489A (en) * 1984-10-15 1988-01-19 Douglas Shander Hair growth modification with ornithine decarboxylase inhibitors
ATE95430T1 (de) * 1984-12-22 1993-10-15 Sanol Arznei Schwarz Gmbh Wirkstoffpflaster.
US4883669A (en) 1985-02-25 1989-11-28 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for estradiol and other estrogenic steroids and process for administration
DD251567A1 (de) * 1986-07-30 1987-11-18 Jenapharm Veb Verfahren zur herstellung gefaerbter, selbstklebender loesungsmittelhaltiger polymermischungen
CN1021196C (zh) 1986-12-29 1993-06-16 新泽西州州立大学(鲁杰斯) 透皮雌激素/孕激素药剂单元、系统及方法
CH674618A5 (pl) 1987-04-02 1990-06-29 Ciba Geigy Ag
DE3743946A1 (de) 1987-09-01 1989-03-09 Lohmann Gmbh & Co Kg Vorrichtung zur abgabe von nitroglycerin an die haut, verfahren zu ihrer herstellung sowie ihre verwendung
US4906475A (en) 1988-02-16 1990-03-06 Paco Pharmaceutical Services Estradiol transdermal delivery system
JPH02180835A (ja) * 1988-12-29 1990-07-13 Lion Corp 外用製剤
EP0409383B1 (en) * 1989-07-21 1994-04-06 Izhak Blank Estradiol compositions and methods for topical applications
CA2065311C (en) * 1989-09-08 2000-01-11 Chia-Ming Chiang Solid matrix system for transdermal drug delivery
JP3273430B2 (ja) * 1989-12-28 2002-04-08 日東電工株式会社 エストロゲン含有ゲル製剤
DE4115849A1 (de) * 1991-05-15 1992-11-19 Lohmann Therapie Syst Lts Penetrationsfoerdernde substanz
JPH04342532A (ja) * 1991-05-21 1992-11-30 Sekisui Chem Co Ltd 経皮吸収貼付剤
JP3086288B2 (ja) * 1991-07-23 2000-09-11 扶桑薬品工業株式会社 経皮吸収製剤
JPH05148135A (ja) * 1991-11-29 1993-06-15 L T T Kenkyusho:Kk 貼付剤用物理的吸収促進剤及びそれを含む貼付剤
DE4230588C1 (de) * 1992-09-12 1993-10-07 Lohmann Therapie Syst Lts Dexpanthenol-haltiges Pflaster zur transdermalen Applikation von Steroidhormonen und Verfahren zu seiner Herstellung
JP2569396B2 (ja) * 1992-12-04 1997-01-08 株式会社太平洋 経皮投与型薬物用貼付剤
JP3197102B2 (ja) * 1993-03-29 2001-08-13 積水化学工業株式会社 経皮吸収製剤及びその製造方法
JP3305101B2 (ja) * 1994-03-29 2002-07-22 積水化学工業株式会社 経皮吸収製剤
DE4416927C1 (de) * 1994-05-13 1995-08-31 Lohmann Therapie Syst Lts Vorrichtung zur Abgabe von Wirkstoffen aus Haftschmelzklebern, Verfahren zu ihrer Herstellung und ihre Verwendung
JPH0827003A (ja) * 1994-07-22 1996-01-30 Sekisui Chem Co Ltd 経皮吸収製剤
AU692944B2 (en) * 1994-11-18 1998-06-18 Hisamitsu Pharmaceutical Co., Inc. Percutaneously absorbable patch
CA2183960E (en) * 1994-12-24 2001-08-21 Jung Ju Kim Medicinal patches for percutaneous administration
HU228434B1 (en) * 1995-06-07 2013-03-28 Ortho Mcneil Pharm Inc Transdermal medicament for administering 17-deacetyl norgestimate alone or in combination with an estrogen
US5783208A (en) * 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid
US5948433A (en) * 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch

Also Published As

Publication number Publication date
US6531149B1 (en) 2003-03-11
CA2338859C (en) 2007-09-18
ES2220093T3 (es) 2004-12-01
ATE264097T1 (de) 2004-04-15
CN1310614A (zh) 2001-08-29
AU758107B2 (en) 2003-03-13
IL141033A (en) 2009-06-15
ZA200100719B (en) 2002-06-14
CN1172661C (zh) 2004-10-27
AU5160799A (en) 2000-02-21
KR100559089B1 (ko) 2006-03-13
KR20010079571A (ko) 2001-08-22
EP1100477A1 (de) 2001-05-23
BR9912687A (pt) 2001-06-05
AR021459A1 (es) 2002-07-24
PL345695A1 (en) 2002-01-02
DE19834007C1 (de) 2000-02-24
IL141033A0 (en) 2002-02-10
TW542726B (en) 2003-07-21
WO2000006131A1 (de) 2000-02-10
CA2338859A1 (en) 2000-02-10
DE59909189D1 (de) 2004-05-19
PL194102B1 (pl) 2007-04-30
JP2002521427A (ja) 2002-07-16
TR200100289T2 (tr) 2001-07-23

Similar Documents

Publication Publication Date Title
EP0802789B1 (de) Estradiolhaltiges pflaster
EP1100477B1 (de) Pflaster, die zur transdermalen Applikation von Estradiol geeignet sind, und Wollwachs oder Bestandteile davon sowie Zinkoxid enthalten
DE4336557C2 (de) Estradiolhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
DE4400770C1 (de) Wirkstoffhaltiges Pflaster zur Abgabe von Estradiol mit mindestens einem Penetrationsverstärker, Verfahren zu seiner Herstellung und seine Verwendung
EP0421454B1 (de) Oestrogenhaltiges Wirkstoffpflaster
DE19728517C2 (de) TTS zur Verabreichung von Sexualsteroidhormonen und Verfahren zu seiner Herstellung
DE4230588C1 (de) Dexpanthenol-haltiges Pflaster zur transdermalen Applikation von Steroidhormonen und Verfahren zu seiner Herstellung
WO2000006130A1 (de) Estradiolhaltiges pflaster zur transdermalen applikation von hormonen
EP2234605B1 (de) Transdermales therapeutisches system mit harnstoff-komponente
MXPA01001042A (en) Estradiol-containing patch for transdermal administration of hormones
MXPA01001043A (en) Estradiol-containing patch for transdermal administration of hormones
DE29923292U1 (de) TTS zur Verabreichung von Sexualsteroidhormonen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001223

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RTI1 Title (correction)

Free format text: PATCH SUITABLE FOR THE TRANSDERMAL ADMINISTRATION OF ESTRADIOL COMPRISING WOOL WAX OR ITS COMPONENTS AND ZINC OXIDE

RTI1 Title (correction)

Free format text: PATCH COMPRISING WOOL FAT OR ITS COMPONENTS AND ZINC OXIDE, SUITABLE FOR THE TRANSDERMAL ADMINISTRATION OF ESTRADIOL

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040414

Ref country code: IE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040414

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040414

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040414

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 59909189

Country of ref document: DE

Date of ref document: 20040519

Kind code of ref document: P

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: GERMAN

GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)

Effective date: 20040520

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040714

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040714

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040714

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040716

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040716

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040731

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040731

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040731

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040731

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20040414

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2220093

Country of ref document: ES

Kind code of ref document: T3

Ref country code: IE

Ref legal event code: FD4D

BERE Be: lapsed

Owner name: LOHMANN THERAPIE-SYSTEME A.G. *LTS

Effective date: 20040731

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

26N No opposition filed

Effective date: 20050117

BERE Be: lapsed

Owner name: LOHMANN THERAPIE-SYSTEME A.G. *LTS

Effective date: 20040731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040914

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20110729

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20110721

Year of fee payment: 13

Ref country code: ES

Payment date: 20110726

Year of fee payment: 13

Ref country code: DE

Payment date: 20110722

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20110722

Year of fee payment: 13

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20120716

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20130329

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130201

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120716

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120716

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 59909189

Country of ref document: DE

Effective date: 20130201

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20131018

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120717